Корвалтаб is commonly used across therapeutic domains where symptomatic support for central nervous system over-excitation is needed. The primary benefit focuses on providing general calming and spasmolytic relief, which assists with maintaining functional stability and helps ease the overall symptom burden when patients experience heightened discomfort.

The medication is applied in addressing symptom clusters that may become intense or disruptive, including nervous tension, irritability, and sleeplessness linked to functional conditions. It is considered relevant for easing tachycardia and non-acute coronary vessel tension associated with neurovegetative disorders, as well as providing supportive relief for intestinal cramps and other smooth muscle spasms.

“It supports the patient during difficult episodes by promoting a state of general restfulness and contributes to improved comfort.”

This medication is often used when symptoms intensify and short-term symptomatic assistance is needed, such as during phases of increased distress or discomfort associated with neuroses or vegetative-vascular dystonia.

---

Quick Fact: Relief for Nervous and Visceral Tension

Корвалтаб is commonly used for managing conditions characterized by periods of heightened symptoms where both emotional and physical tension are pronounced. It helps patients cope more steadily with symptom fluctuations by providing supportive relief when symptoms interfere with routine activities.

Regulatory References

1. NIH MedlinePlus Drug Information

The official eligibility for Корвалтаб is strictly governed by the regulatory profile of its main component, Phenobarbital. This medicine is primarily intended for use in the adult population when no specific contraindications are present.

Populations for Whom Use is Contraindicated

Regulatory authorities explicitly prohibit the use of this medicine in populations with:

• Hypersensitivity: Known allergy to Phenobarbital, other barbiturates, or any component of the formulation.
• Severe Organ Impairment: Including marked hepatic impairment or severe respiratory depression.
• Comorbidities: History of acute intermittent porphyria or known addiction to sedative-hypnotic medicines.

Age and Conditional Restrictions

Use requires caution or is not generally recommended for specific populations as documented in prescribing information:

• Pregnancy and Lactation: It is contraindicated in pregnancy (Category D) due to potential fetal harm, and generally not recommended for women who are breastfeeding. Women of childbearing potential are advised to use effective non-hormonal contraception.
• Age Groups: Use in older adults (65+ years) requires caution due to the potential for marked excitement or confusion. The medicine is contraindicated in hyperkinetic children.
• Conditional Use: Caution is necessary for patients with severe renal impairment, mental depression, or uncontrolled diabetes mellitus.

This strict regulatory framework defines the narrow population eligible for treatment.

Interactions with other medicines and products

The interaction profile of Корвалтаб, primarily driven by its Phenobarbital component, is characterized by two major documented mechanisms: hepatic enzyme induction and additive central nervous system (CNS) depression, as detailed in regulatory prescribing information.

---

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type	Interacting Substances	Official Regulatory Outcome
Metabolic (Enzyme Induction)	Oral Contraceptives, Coumarin Anticoagulants, Corticosteroids, certain Antifungals	Causes decreased plasma concentrations and reduced efficacy of co-administered drugs by acting as a potent inducer of hepatic enzymes, including CYP1A2, CYP2C9, and CYP3A4.
Pharmacodynamic	Alcohol (Ethanol), Opioids, other CNS Depressants (e.g., tranquilizers, sleep medicines)	Results in additive CNS depressant effects, which may lead to profound sedation, respiratory depression, and life-threatening risk.

---

Regulatory Restrictions and Population Notes

The co-administration of the medicine with Sodium Oxybates and certain cobicistat-containing HIV/AIDS medications is contraindicated due to the documented risk of severe pharmacodynamic synergism or loss of virologic response. Co-administration with Opioids is severely restricted. Furthermore, the herbal product St. John's Wort may reduce the effect of the Phenobarbital component. Caution is required for use in patients with decreased liver function due to the enzyme-inducing activity.

Корвалтаб functions via two primary components: phenobarbital and ethyl alpha-bromoisovalerate (the active metabolite of its valerian component). Phenobarbital, a barbiturate, acts as a positive allosteric modulator at the GABAA receptor complex in the central nervous system. This interaction facilitates a conformational change in the receptor, prolonging the opening time of the integral chloride ion channel. The sustained influx of chloride ions ( Cl^-) into the postsynaptic neuron causes hyperpolarization of the neuronal membrane, thereby increasing the threshold for action potential generation. This intracellular cascade leads to a reduction in overall neuronal excitability and decreased synaptic transmission within the central nervous system.

The alpha-bromoisovaleric acid metabolite of the valerian component contributes to the GABAergic effect, specifically through a partial agonist action on central GABAA receptors. This dual GABAA receptor modulation promotes an increased inhibitory tone across the neuroaxis. The resultant system-level physiological consequence is a generalized modulation of central nervous system activity.

Official Administration Guidelines

Корвалтаб is a combination medication containing Phenobarbital that is approved for use via the oral route in two primary forms: tablets and liquid drops. The official instructions for use are defined in the regions where the product is marketed, establishing a short-term, symptomatic administration protocol.

Dosing and Administration Schedule

Administration Scope	Official Instruction
Route of Administration	Oral
Dosing Regimen (Adults)	Tablets: 1 to 2 tablets per dose. Drops: 15 to 30 drops per dose.
Frequency Pattern	Typically 2 to 3 times per day, used intermittently as needed for symptomatic management.
Maximum Single Dose	May be increased up to 3 tablets or 40 to 50 drops for intense episodes.

Procedural and Contextual Instructions

Administration is generally specified to occur before meals. When using the oral solution, the prescribed number of drops should be diluted with a small amount of water or placed on a sugar cube before intake. Tablets should be swallowed whole with water.

Since this medication contains Phenobarbital, a substance recognized for its potential for dependence, its use is structured as short-term and intermittent. For the older adult population, official guidance on the core component, Phenobarbital, suggests a need for reduced doses, as this group may be more susceptible to central nervous system effects. Following prolonged use, it is required that the medicine be withdrawn gradually to avoid adverse reactions.

Корвалтаб: Recent Clinical Evidence

Research on the combination ingredients found in Корвалтаб (typically containing phenobarbital, ethyl alpha-bromisovalerate, and peppermint oil) focuses primarily on their combined effect on the central nervous system, particularly for symptoms associated with neuroses, anxiety, and sleep disturbances.

Evaluation of Combined Efficacy

Clinical studies have evaluated whether the combination of these components is associated with a calming effect. Investigations have examined the potential of the ingredients to lessen nervous system excitability, which is a key area of interest for treating functional neuroses. The limited available research typically assesses the drug's impact on subjective patient-reported outcomes, such as self-assessed stress levels or perceived difficulty falling asleep.

Safety and Tolerability Profiles

Research has explored the safety and tolerability profiles of the components, particularly phenobarbital, which is known to be a sedative agent. Studies often report on the incidence and nature of adverse events observed in adult populations during the period of use. Specific attention has been paid to the potential for residual drowsiness or dependency concerns associated with the barbiturate component.

Ongoing and Exploratory Research

Currently, many studies focus on the individual active ingredients rather than the finished product, seeking to understand their precise mechanisms. Ongoing research continues to evaluate the duration of effect and potential interactions with other commonly used medications. Limited exploratory studies have examined the potential for use in mitigating mild functional disorders beyond the primary, approved indications.

Common questions about Корвалтаб (FAQ)

---

Q: What is the maximum daily dose I can take?

Official product information emphasizes the importance of staying within the maximum recommended limits to prevent the risk of overdose and potential liver damage. The total amount of paracetamol consumed within a 24-hour period should not exceed the established maximum limit, and this includes all sources of the medicine.

---

Q: What are the common side effects of this medicine?

According to regulatory documents, most people tolerate the medicine well when used according to label instructions. If signs of a severe allergic reaction (such as a rash, swelling, or difficulty breathing) or symptoms of liver damage (like yellowing of the skin or eyes, or pain in the upper belly) are noticed, immediate medical attention is necessary, and use of the medicine should be discontinued.

---

Q: Can I take this if I have liver disease?

Official warnings state that this medicine is contraindicated, meaning it should not be used, if severe hepatic dysfunction or liver failure is present. For people with existing liver impairment or a history of chronic alcohol consumption, the medicine must be used with caution. Determining appropriateness requires consultation with a healthcare professional.

---

Q: Is it safe to use during pregnancy?

Paracetamol remains a common option for pain relief during pregnancy, according to official guidance. It is generally advised that the lowest effective dose should be used for the shortest necessary duration. This approach helps manage pain and fever, as untreated conditions could pose risks.

---

Q: How should I store this medicine?

Compliance with storage instructions printed on the product label is necessary to maintain the medicine's effectiveness. This typically involves keeping the medicine in its original package and storing it below a specified temperature. The product should be stored out of sight and reach of children.

---

Q: Can I take this with alcohol?

Official safety warnings indicate an increased risk of severe liver damage when this medicine is combined with regular, heavy consumption of alcohol. Chronic alcohol consumption can lower the body's tolerance threshold for paracetamol.

---

Q: Does it make you sleepy or drowsy?

Standard regulatory documents for single-ingredient paracetamol products do not commonly list drowsiness as a frequent or significant side effect. Therefore, regulatory documents typically do not list drowsiness as a common side effect requiring a specific warning regarding driving or operating machinery.

---

Q: Can I take it for migraines?

Regulatory indications include the use of the medicine for the symptomatic relief of mild to moderate pain. This officially covers various types of headaches, including migraine pain.

---

Q: Is it safe for children under 2 years old?

Official product information for liquid formulations provides specific pediatric dosing instructions based on the child's weight and age, sometimes covering infants. Reference to the specific dosage chart and age restrictions on the product label is necessary, as use varies by product formulation.

---

Q: Is it safe to take for a long time (long-term use)?

For non-prescription use, official guidance often recommends that the medicine should not be taken for more than a few days without professional review. Prolonged or frequent use, especially at high doses, has been associated with a risk of serious adverse effects, including damage to the liver or kidneys.

Storage and Disposal Requirements

Official regulatory guidelines define specific conditions for storing and disposing of medicines containing controlled substances like Phenobarbital. The tablets must be stored at Controlled Room Temperature, specifically 20^circ-25 C (68^circ-77 F), with protection required from both light and moisture to maintain product stability.

Due to its composition, the medicine must be stored in a safe, secure place and kept strictly out of the sight and reach of children using a child-resistant closure.

Disposal must adhere to controlled substance regulations. It is illegal to sell or give away unused portions. Consult a pharmacist or a local drug take-back program for the official procedure to dispose of the unused or expired product.